SimonMed has launched its DEXA + TBS (Trabecular Bone Score), a next-gen bone health screening that combines bone density and bone quality analysis. It aims to set a new standard of care in osteoporosis detection and fracture prevention.

The technology was developed in collaboration with Medimaps Group. DEXA + TBS integrates U.S. Food and Drug Administration (FDA)-approved software into standard DEXA scans to measure both bone mineral density (BMD) and trabecular bone score (TBS) to evaluate bone microarchitecture.

The dual analysis lets clinicians spot up to 30% more patients at high fracture risk, even when bone density appears normal.

“Osteoporosis is often diagnosed too late—after a fracture has already impacted quality of life,” said Dr. John Simon, founder and CEO of SimonMed Imaging. “With DEXA +  TBS, we’re giving patients and providers a more complete picture of bone health so  they can make proactive decisions earlier, to prevent and treat the disease.”

DEXA + TBS is available at more than 80 SimonMed locations equipped with DEXA technology.

“Our partnership with SimonMed is about shifting from reactive to proactive care,” said  Univ.-Prof. Dr. Didier Hans, co-founder and CEO of Medimaps Group. “By expanding  access to advanced diagnostics like TBS, we enable smarter, earlier decisions that  prevent fractures and improve outcomes.”